COMPASS PATHWAYS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.37 USD | -0.67% |
|
-1.47% | -15.77% |
| May. 22 | Clarify Pharma confirms name change to File Forge | AN |
| May. 09 | Transcript : COMPASS Pathways plc - Shareholder/Analyst Call |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 504M |
|---|---|---|---|---|---|
| Net income 2024 * | -145M | Net income 2025 * | -164M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 297M | Net cash position 2025 * | 263M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.35
x | P/E ratio 2025 * |
-3.55
x | Employees | 186 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.69% |
More Fundamentals
* Assessed data
More news
Latest transcript on COMPASS Pathways plc
More recommendations
More press releases
| 1 day | -0.67% | ||
| 1 week | -1.47% | ||
| Current month | -0.14% | ||
| 1 month | -14.00% | ||
| 3 months | -28.24% | ||
| 6 months | +23.24% | ||
| Current year | -15.77% |
1 week
7.24
7.73
1 month
7.249.63
Current year
7.2412.75
1 year
5.0112.75
3 years
5.0149.52
5 years
5.0161.69
10 years
5.0161.69
| Managers | Title | Age | Since |
|---|---|---|---|
Kabir Kumar Nath
CEO | Chief Executive Officer | 59 | 22-07-31 |
Greg Ryslik
CTO | Chief Tech/Sci/R&D Officer | - | - |
Guy Goodwin
CTO | Chief Tech/Sci/R&D Officer | 76 | 21-07-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Linda McGoldrick
BRD | Director/Board Member | 69 | 20-08-31 |
David Norton
CHM | Chairman | 72 | 18-04-30 |
Robert McQuade
BRD | Director/Board Member | 67 | 20-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 7.38 | -0.54% | 397,960 |
| 24-05-30 | 7.42 | -0.40% | 261,093 |
| 24-05-29 | 7.45 | +0.13% | 192,017 |
| 24-05-28 | 7.44 | -0.53% | 441,832 |
| 24-05-24 | 7.48 | +0.27% | 231,375 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Companyâs initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.38
USD
Average target price
41.25
USD
Spread / Average Target
+458.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.77% | 504M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- CMPS Stock
